Marco Meglio

Using rigorous cell-based assays, cerebrospinal fluid GFAP levels were significantly lower in double-seronegative NMOSD than AQP4-positive NMOSD but did not differ between those with MOGAD or other neurological diseases.

The double-blind, placebo-controlled, randomized trial will evaluate CT1812, a small molecule therapeutic designed to address the dual assault from α-synuclein and amyloid-ß oligomers in patients with dementia with Lewy bodies.

Previously used to treat conditions such as temporal lobe epilepsy and focal impaired awareness, the FDA approved a new oral suspension of zonisamide, an antiseizure medication on the market for over 2 decades.

Neuropathic pain and constipation coexisted in 43.5% of the survey participants, and approximately one-third of patients with both symptoms reported a possible link between the two.

Between AQP4-IgG-positive and negative patients with NMOSD, there were no significant differences in cognitive performance, despite having similar demographic and clinical characteristics.

Those randomly assigned to cognitive behavioral therapy reported significantly lower aggregate posttreatment mean HIT-6 scores compared with standard care, but the posttreatment effect for cognitive processing therapy vs treatment per usual was modest.

The new phase 2b trial expands on successful phase 2a findings, in which treatment with SCI-110 resulted in a 21% reduction in tics across a cohort of adults with Tourette syndrome.

In a meta-analysis spanning 10 studies of 1300 patients with Alzheimer disease, global cognition, as measured by the Mini-Mental State Examination or ADAS-Cog, was improved using noradrenergic drugs.

The presence of concurrent psychogenic nonepileptic seizures increased the odds of hospitalization for first suicide by 152% compared with epilepsy alone.

In comparison with controls, there were no significant differences in MRI volumes, amyloid-ß or tau accumulation, nor in most longitudinal measures among those with traumatic brain injury and/or PTSD.

In comparison to those with consistently low depressive symptoms, those with consistently high, fluctuating, and increasing depressive trajectories had 18% to 31% higher hazard of developing incident stroke.

The chair of Cleveland Clinic’s Department of Physical Medicine provided commentary on the goals for the newly approved EksoNR robotic exoskeleton in rehabilitative efforts for patients with multiple sclerosis.

Over a 2-year period, apitegromab-treated patients demonstrated sizable and sustained improvements in Hammersmith Functional Motor Scale-Expanded and substantial increases in Revised Upper Limb Module scores.

The risk of developing Alzheimer disease and related dementias decreased gradually with increasing scores in a dose-response manner on a model geared toward identifying healthy lifestyle factors.

Taldefgrobep alfa, a muscle-targeted experimental treatment potentially used in combination with other SMA therapies, will be evaluated in a cohort of 180 patients with SMA, regardless of ambulatory status or disease classification.

On a per-capita basis, a hospital serving a predominately Black, racially segregated community was 26% less likely to adopt stroke certification of any level than a hospital in a predominately non-Black, racially segregated community.

Of the patients with drug-resistant epilepsy in the cohort, 54% had status epilepticus during their acute admission, and 2 of 3 patients with NORSE ended up developing drug-resistant epilepsy at 12 months.

The net clinical benefit with ticagrelor and aspirin over clopidogrel and aspirin treatment may be predominant in the first week, with additional small benefit in the second and third weeks for those with minor ischemic stroke or transient ischemic attack.

Ruth Benca, MD, PhD, a professor and the chair of Psychiatry & Human Behavior at Wake Forest School of Medicine, provided insight on the age- and sex-related differences in sleep disorders, and the needed research on the effects of therapeutics in older populations.

In addition to filing under the accelerated approval pathway, Eisai will submit for a traditional approval of lecenamab before the end of the first quarter of 2023, seeking an indication for mild cognitive impairment because of Alzheimer disease.

In the original panel discussion, held in March 2022, the majority of members of the committee voted that AMX0035 did not fully demonstrate sufficient efficacy as a treatment for ALS.

The chair of Cleveland Clinic’s Department of Physical Medicine discussed a new rehabilitative approach using a robotic exoskeleton to improve fatigue and gait in patients with multiple sclerosis.

All 12 of the children met diagnostic criteria for multiple sclerosis and were seropositive for MOG-IgG at baseline experienced a disease course different than typical MS through the observed time.

Alectos to receive a $15 million upfront payment from Biogen and is eligible to receive upward of $630 million pending the success of the collaboration and achieving future milestones for the investigational PD treatment.

Using a large-scale bank of participants, investigators found an association between Alzheimer disease polygenetic risk score and depression, which was not explained by presence of APOE ε4 allele.

Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.

In triptan users, prescriptions of cardiac therapies and beta blockers were significantly more common compared with other prescriptions of calcium channel blockers and renin/angiotensin inhibitors, which were significantly less common.

Despite not reaching the primary end point, the oromucosal spray is still being evaluated in 2 ongoing trials that comprise of 446 and 190 patients, respectively, with spasticity due to multiple sclerosis.

Patients with high levels of neurofilament light at baseline had an increased risk of developing new T2 lesions and of experiencing a new clinical relapse in the follow-up period, but not of EDSS progression.

Following positive phase 2a findings, NeuroSense’s agent PrimeC continued to show a mechanistic impact on biomarkers specific to patients with amyotrophic lateral sclerosis.